Literature DB >> 9624493

Quantitative structure-activity relationship studies of a series of sulfa drugs as inhibitors of Pneumocystis carinii dihydropteroate synthetase.

T Johnson1, I A Khan, M A Avery, J Grant, S R Meshnick.   

Abstract

Sulfone and sulfanilamide sulfa drugs have been shown to inhibit dihydropteroate synthetase (DHPS) isolated from Pneumocystis carinii. In order to develop a pharmacophoric model for this inhibition, quantitative structure-activity relationships (QSAR) for sulfa drugs active against DHPS have been studied. Accurate 50% inhibitory concentrations were collected for 44 analogs, and other parameters, such as partition coefficients and molar refractivity, were calculated. Conventional multiple regression analysis of these data did not provide acceptable QSAR. However, three-dimensional QSAR provided by comparative molecular field analysis did give excellent results. Upon removal of poorly correlated analogs, a data set of 36 analogs, all having a common NHSO2 group, provided a cross-validated r2 value of 0.699 and conventional r2 value of 0.964. The resulting pharmacophore model should be useful for understanding and predicting the binding of DHPS by new sulfa drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624493      PMCID: PMC105621     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors.

Authors:  M C Nicklaus; G W Milne; T R Burke
Journal:  J Comput Aided Mol Des       Date:  1992-10       Impact factor: 3.686

2.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Authors:  R D Cramer; D E Patterson; J D Bunce
Journal:  J Am Chem Soc       Date:  1988-08-01       Impact factor: 15.419

Review 3.  Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

Authors:  R J Simonds; W T Hughes; J Feinberg; T R Navin
Journal:  Clin Infect Dis       Date:  1995-08       Impact factor: 9.079

4.  A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors.

Authors:  W Tong; E R Collantes; Y Chen; W J Welsh
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

5.  Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi.

Authors:  J C Edman; J A Kovacs; H Masur; D V Santi; H J Elwood; M L Sogin
Journal:  Nature       Date:  1988-08-11       Impact factor: 49.962

6.  Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group.

Authors:  S Safrin; D M Finkelstein; J Feinberg; P Frame; G Simpson; A Wu; T Cheung; R Soeiro; P Hojczyk; J R Black
Journal:  Ann Intern Med       Date:  1996-05-01       Impact factor: 25.391

7.  Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.

Authors:  Y L Hong; P A Hossler; D H Calhoun; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  7 in total
  2 in total

1.  Chitinases in Pneumocystis carinii pneumonia.

Authors:  Leah R Villegas; Theodore J Kottom; Andrew H Limper
Journal:  Med Microbiol Immunol       Date:  2012-04-26       Impact factor: 3.402

2.  Genome-scale reconstruction of the metabolic network in Staphylococcus aureus N315: an initial draft to the two-dimensional annotation.

Authors:  Scott A Becker; Bernhard Ø Palsson
Journal:  BMC Microbiol       Date:  2005-03-07       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.